Chronic traumatic encephalopathy (CTE) is a neurodegenerative condition characterised by the abnormal accumulation of hyperphosphorylated tau protein within the cerebral cortex. We describe the first neuropathological report of CTE from New Zealand.
Full article available to subscribers
Chronic traumatic encephalopathy (CTE) is a neurodegenerative condition characterised by the abnormal accumulation of hyperphosphorylated tau protein within the cerebral cortex. We describe the first neuropathological report of CTE from New Zealand.
The decedent, a New Zealand European male, died in 2021 aged 79 years. He played rugby from 9 years of age and participated in high school boxing and rugby league. He represented New Zealand in rugby league during the 1960s and early 1970s before retiring in his late 30s. He sustained multiple “minor” head knocks (one resulting in hospitalisation). At age 64 he was diagnosed with Parkinson’s disease by a neurologist based on motor features, and was prescribed L-dopa. At age 70 neuropsychiatric aspects including cognitive difficulties, apathy and low mood had emerged. Dementia developed over the latter part of his life, requiring hospital-level care. His brain was donated to the Neurological Foundation Human Brain Bank.
At neuropathological examination, the formalin-fixed brain weighed 1,142g. There was widespread cortical atrophy, most noticeable frontally, and a pale substantia nigra. Histological examination confirmed brainstem, limbic and neocortical/diffuse Lewy body disease1 consistent with Parkinson’s disease (Figure 1). There was cortical and sub-cortical beta-amyloid deposition (Thal phase 3)1 with type 2 cerebral amyloid angiopathy (CAA).2 Additional neuropathologic findings included: hippocampal sclerosis with hippocampal TDP-43-positive inclusions; medial temporal lobe tau-positive neurofibrillary tangles (NFTs) and neuropil threads (Braak stage II)1 (Figure 1); and patchy changes of age-related tau astrogliopathy (ARTAG)3 (Figure 2).
View Figure 1–2.
In addition, perivascular tau-positive NFTs were visible in the depths of several sulci in the occipital cortex and inferior parietal lobule consistent with the lesion of CTE (red arrow, Figure 2). NFTs were visible in the bank and crest of adjacent gyri and superficial cortical laminae. NFTs were also present within the hippocampus (CA1 and CA4), amygdala, thalamus and dentate nucleus, consistent with high-stage CTE.4,5
Final neuropathologic diagnoses of neocortical Lewy body disease, high-stage CTE, low-level Alzheimer-disease neuropathologic change (NIA-AA score A2 B1 C1), stage 2 limbic age-related TDP-43 encephalopathy (LATE-NC),6 ARTAG and type 2 CAA were rendered.
CTE is defined pathologically by perivascular neuronal hyperphosphorylated tau aggregates, with or without astrocytes, in the depths of cortical sulci in the cerebral cortex.4 The only recognised cause of CTE is prior exposure to repetitive head impacts (RHI) such as that due to participation in contact sports or military service. 4 Determining the prevalence of CTE is difficult. CTE rates of 9–31.8% in contact sport participants have been reported in brain bank cohorts.7,8 Extended exposure to RHI increases the risk of CTE.9
“Traumatic encephalopathy syndrome” has been applied when CTE is suspected during life based on relevant history and a non-specific neuropsychiatric syndrome of irritability, impulsivity, depression and memory decline.4 With advancing disease, gait and speech abnormalities, parkinsonism and frank dementia typically emerge. In our patient, the parkinsonism, with early cognitive and neuropsychiatric manifestations, was most likely due to a combination of the Lewy body disease and CTE.
The older an individual with dementia, the less likely a single pathology is responsible. As in this case, comorbid neuropathologic processes (e.g., Alzheimer’s disease and Lewy body pathology) are described in conjunction with CTE.10 The relative contribution of the multiple neurodegenerative pathologies to the clinical picture in our case cannot be stated with confidence and no pathological criteria exist to make this distinction. CTE may develop in early adult life, when such confounding variables are less likely.9
CTE should be considered in any individual at risk of RHI and may be seen in conjunction with other neuropathologic processes. Post-mortem examination is the only way to definitively diagnose CTE—and should be considered in any individual with neuropsychiatric features and a history of RHI.
Fen-Lan Cherry Chang: Registrar, Anatomical Pathology, Pathology and Laboratory Medicine, Auckland City Hospital, New Zealand.
Richard LM Faull: Distinguished Professor, Centre for Brain Research and Department of Anatomy and Medical Imaging, The University of Auckland, New Zealand.
Maurice A Curtis: Professor, Centre for Brain Research and Department of Anatomy and Medical Imaging, The University of Auckland, New Zealand.
Andrew M Chancellor: Neurologist, Department of Neurology, Tauranga Hospital; Honorary Senior Lecturer, The University of Auckland, New Zealand.
Michael E Buckland: Neuropathologist, Department of Neuropathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Clinton P Turner: Consultant Pathologist, Anatomical Pathology, Pathology and Laboratory Medicine, Auckland City Hospital; Honorary Senior Lecturer, Centre for Brain Research and Department of Anatomy and Medical Imaging, The University of Auckland, New Zealand.
We thank the patient and their family for their donation to the Neurological Foundation Human Brain Bank.
Dr Clinton P Turner: Anatomical Pathology, Pathology and Laboratory Medicine, Auckland City Hospital, Te Toka Tumai, Park Road, Grafton, Auckland 1148.
Nil.
1) Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012 Jan;123(1):1-11. doi: 10.1007/s00401-011-0910-3.
2) Thal DR, Ghebremedhin E, Rüb U, et al. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002 Mar;61(3):282-93. doi: 10.1093/jnen/61.3.282.
3) Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016 Jan;131(1):87-102. doi: 10.1007/s00401-015-1509-x.
4) McKee AC, Stein TD, Huber BR, et al. Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impacts. Acta Neuropathol. 2023 Apr;145(4):371-94. doi: 10.1007/s00401-023-02540-w.
5) Bieniek KF, Cairns NJ, Crary JF, et al. The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol. 2021 Feb 22;80(3):210-9. doi: 10.1093/jnen/nlab001.
6) Nelson PT, Lee EB, Cykowski MD, et al. LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 2023 Feb;145(2):159-73. doi: 10.1007/s00401-022-02524-2.
7) Bieniek KF, Blessing MM, Heckman MG, et al. Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study. Brain Pathol. 2020;30(1):63-74. doi: 10.1111/bpa.12757.
8) Bieniek KF, Ross OA, Cormier KA, et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol. 2015 Dec;130(6):877-89. doi: 10.1007/s00401-015-1502-4.
9) McKee AC, Mez J, Abdolmohammadi B, et al. Neuropathologic and Clinical Findings in Young Contact Sport Athletes Exposed to Repetitive Head Impacts. JAMA Neurol. 2023 Oct 1;80(10):1037-50. doi: 10.1001/jamaneurol.2023.2907.
10) McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 Jan;136(Pt 1):43-64. doi: 10.1093/brain/aws307.
Sign in to view your account and access
the latest publications by the NZMJ.
Don't have an account?
Let's get started with creating an account.
Already have an account?
Become a member to enjoy unlimited digital access and support the ongoing publication of the New Zealand Medical Journal.
The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers. Institutions are encouraged to subscribe. The value of institutional subscriptions is essential to the NZMJ, as supporting a reputable medical journal demonstrates an institution’s commitment to academic excellence and professional development. By continuing to pay for a subscription, institutions signal their support for valuable medical research and contribute to the journal's continued success.
Please email us at nzmj@pmagroup.co.nz